Boryung Pharmaceutical Co., Ltd
Clinical trials sponsored by Boryung Pharmaceutical Co., Ltd, explained in plain language.
-
New dosing strategy aims to reduce side effects in schizophrenia treatment
Disease control Recruiting nowThis study tests a new, slower way to increase the dose of olanzapine for people with schizophrenia. The goal is to see if this approach is safer and still controls symptoms effectively. About 120 adults with schizophrenia will take part, and researchers will monitor side effects…
Phase: PHASE2 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 16, 2026 22:31 UTC
-
Diabetes drug switch may improve blood sugar control
Disease control Recruiting nowThis study tests whether changing from one diabetes medication combination to another can better control blood sugar in adults with type 2 diabetes. About 204 participants will be randomly assigned to either stay on their current drugs or switch to a new combination. The main goa…
Phase: PHASE4 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 16, 2026 22:30 UTC
-
New drug zepzelca tracked in real-world lung cancer patients
Disease control Recruiting nowThis study follows about 300 people with metastatic small cell lung cancer whose first chemotherapy stopped working. Researchers want to see how well the drug Zepzelca works and what side effects occur when used in everyday medical practice. The main goal is to measure how many p…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New study tracks diabetes Drug's dual benefits for blood pressure
Disease control Recruiting nowThis study is observing how well the drug dapagliflozin works and how safe it is for people with type 2 diabetes who also have high blood pressure. Researchers will track blood sugar and blood pressure control in 9,000 participants over time. The goal is to see if this medication…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo pill aims to simplify cholesterol management
Disease control Recruiting nowThis study is testing a single pill that combines two medicines (pitavastatin and ezetimibe) to lower cholesterol in people with high cholesterol or mixed lipid problems. About 8,600 participants will take the pill as part of their normal routine, and researchers will check if it…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
20,000-Person trial tests new combo pill for blood pressure control
Disease control Recruiting nowThis study will follow 20,000 adults with high blood pressure who take a single pill containing two or three medicines (fimasartan/amlodipine with or without hydrochlorothiazide). The main goal is to see how well these pills control blood pressure after 12 weeks and to track hear…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New chemo formula may reduce Alcohol-Like side effects in breast cancer treatment
Symptom relief Recruiting nowThis study looks at whether a new version of the chemotherapy drug docetaxel, which does not contain ethanol (alcohol), causes fewer alcohol-like side effects in breast cancer patients. About 1,052 participants will be observed before and after surgery to track symptoms like flus…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated May 11, 2026 20:38 UTC
-
Bipolar drug study: will learning about weight gain help patients?
Knowledge-focused Recruiting nowThis study will follow 3000 people with bipolar disorder who are taking olanzapine. Researchers want to see what other medications patients use and whether teaching patients about weight gain can help prevent it. This is an observational study, meaning no new treatment is given—j…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated May 16, 2026 22:34 UTC
-
Researchers track Real-World chemo patterns in advanced colorectal cancer
Knowledge-focused Recruiting nowThis study watches 1,000 people with metastatic colorectal cancer whose first chemotherapy stopped working. It aims to see which second or later treatments doctors choose and how well they work. No new drugs are tested; the goal is to learn from real-world practice.
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated May 11, 2026 20:39 UTC